Björn Rissiek Institute of Immunology University Medical Center, Hamburg Biography Publications Institution JoVE Articles Björn Rissiek has not added a biography. If you are Björn Rissiek and would like to personalize this page please email our Author Liaison for assistance. Publications Tuning IL-2 Signaling by ADP-ribosylation of CD25 Scientific Reports. 2015 | Pubmed ID: 25753532 ADP-ribosylation of P2X7: a Matter of Life and Death for Regulatory T Cells and Natural Killer T Cells Current Topics in Microbiology and Immunology. 2015 | Pubmed ID: 25048544 Nanobodies As Modulators of Inflammation: Potential Applications for Acute Brain Injury Frontiers in Cellular Neuroscience. 2014 | Pubmed ID: 25374510 In Vivo Near-infrared Fluorescence Targeting of T Cells: Comparison of Nanobodies and Conventional Monoclonal Antibodies Contrast Media & Molecular Imaging. Mar-Apr, 2014 | Pubmed ID: 24523058 Technical Advance: a New Cell Preparation Strategy That Greatly Improves the Yield of Vital and Functional Tregs and NKT Cells Journal of Leukocyte Biology. Mar, 2014 | Pubmed ID: 24212099 The Art of Blocking ADP-ribosyltransferases (ARTs): Nanobodies As Experimental and Therapeutic Tools to Block Mammalian and Toxin ARTs The FEBS Journal. Aug, 2013 | Pubmed ID: 23627412 Extracellular NAD+ Shapes the Foxp3+ Regulatory T Cell Compartment Through the ART2-P2X7 Pathway The Journal of Experimental Medicine. Nov, 2010 | Pubmed ID: 20975043 A Recombinant Heavy Chain Antibody Approach Blocks ART2 Mediated Deletion of an INKT Cell Population That Upon Activation Inhibits Autoimmune Diabetes Journal of Autoimmunity. Mar, 2010 | Pubmed ID: 19796917 Single Domain Antibodies: Promising Experimental and Therapeutic Tools in Infection and Immunity Medical Microbiology and Immunology. Aug, 2009 | Pubmed ID: 19529959 NAD+ and ATP Released from Injured Cells Induce P2X7-dependent Shedding of CD62L and Externalization of Phosphatidylserine by Murine T Cells Journal of Immunology (Baltimore, Md. : 1950). Mar, 2009 | Pubmed ID: 19234185 Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy Peter Bannas*1, Alexander Lenz*1,2, Valentin Kunick1,2, William Fumey1,2, Björn Rissiek2, Joanna Schmid1,2, Friedrich Haag2, Axel Leingärtner3, Martin Trepel4, Gerhard Adam1, Friedrich Koch-Nolte2 1Department of Diagnostic and Interventional Radiology, University Medical Center, Hamburg, 2Institute of Immunology, University Medical Center, Hamburg, 3University Cancer Center Hamburg, University Medical Center, Hamburg, 4Department of Oncology and Hematology, University Medical Center, Hamburg JoVE 52462 Medicine
Validation of Nanobody and Antibody Based In Vivo Tumor Xenograft NIRF-imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy Peter Bannas*1, Alexander Lenz*1,2, Valentin Kunick1,2, William Fumey1,2, Björn Rissiek2, Joanna Schmid1,2, Friedrich Haag2, Axel Leingärtner3, Martin Trepel4, Gerhard Adam1, Friedrich Koch-Nolte2 1Department of Diagnostic and Interventional Radiology, University Medical Center, Hamburg, 2Institute of Immunology, University Medical Center, Hamburg, 3University Cancer Center Hamburg, University Medical Center, Hamburg, 4Department of Oncology and Hematology, University Medical Center, Hamburg JoVE 52462 Medicine
